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Abstract
Background: The two most commonly used uterotonic drugs in caesarean section are oxytocin and carbetocin, a
synthetic oxytocin analogue. Carbetocin has a longer half-life when compared to oxytocin, resulting in a reduced
use of additional uterotonics. Oxytocin is known to cause fewer cardiovascular side effects when administered as a
short-infusion compared to as an intravenous bolus. Based on these findings, we aim at comparing carbetocin 100
mcg given as a slow intravenous bolus with carbetocin 100 mcg applied as a short-infusion in 100 ml 0.9 % sodium
chloride in women undergoing a planned or unplanned caesarean delivery. We hypothesise uterine contraction not
to be inferior to a bolus application (primary efficacy endpoint) and greater haemodynamic stability to be achieved
after a short-infusion than after a bolus administration, as measured by heart rate and mean arterial blood pressure
(primary safety endpoint).
Methods/Design: This is a prospective, double-blind, randomised controlled, investigator-initiated, non-inferiority
trial taking place at the University Hospital Basel, Switzerland.
Uterine tone is quantified by manual palpation by the obstetrician using a linear analogue scale from 0 to 100 at 2,
3, 5 and 10 minutes after cord clamping. We will evaluate whether the lower limit of the confidence interval for the
difference of the maximal uterine tone within the first 5 minutes after cord clamping between both groups does
not include the pre-specified non-inferiority limit of −10. Both haemodynamic secondary endpoints will be analysed
using a linear regression model, adjusting for the baseline value and the dosage of vasoactive drug given between
cord clamping and 1 minute thereafter, in order to investigate superiority of a short-infusion as compared to a
bolus application.
We will follow the extension of CONSORT guidelines for reporting the results of non-inferiority trials.
Discussion: Haemodynamic stability and adequate uterine tone are important outcomes in caesarean sections. The
results of this trial may be used to optimise these factors and thereby increase patient safety due to a reduction in
cardiovascular side effects.
Trial registration: Clinicaltrials.gov NCT02221531 on 19 August 2014 and www.kofam.ch SNCTP000001197 on 15
November 2014.
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Background
Uterotonic drugs are routinely used after caesarean sec-
tion (CS) to reduce blood loss and the risk of postpar-
tum haemorrhage (PPH) [1]. PPH is defined as a blood
loss of at least 500 ml after vaginal birth and at least
1000 ml after CS and/or the need for blood transfusion
within 24 hours after delivery [2, 3] and represents the
most important cause of maternal morbidity [4]. As
PPH is more common after CS than after vaginal deliv-
ery [5] and as the rate of CS is rising, the incidence of
PPH is expected to increase accordingly.
The two most commonly used uterotonic drugs after
operative delivery are oxytocin and carbetocin, a synthetic
oxytocin analogue. Carbetocin has some advantages over
oxytocin due its four- to ten-times longer half-life [6],
allowing for a single injection. Moreover, a recent meta-
analysis showed that carbetocin significantly reduces the
use of additional uterotonics as compared to oxytocin, al-
though the risk of severe PPH remains similar [7].
Carbetocin is associated with cardiovascular side ef-
fects including hypotension and a compensatory in-
crease in heart rate similar to those of oxytocin [8, 9].
According to randomised trials with oxytocin, the ex-
tent of these cardiovascular side effects seems to be
dependent on dose [10, 11] and the rate of administra-
tion [12]. The manufacturer of oxytocin requires the
drug to be given as a short-infusion to maintain cardio-
vascular stability. In contrast, the manufacturer of car-
betocin recommends a bolus injection of carbetocin.
Whether carbetocin administration as short-infusion of-
fers the optimal balance between contractile benefit to
minimise maternal haemorrhage and reduce cardiovas-
cular side effects is unclear.
In this randomised controlled trial, we aim to investigate
whether carbetocin 100 mcg applied as a short-infusion in
100 ml 0.9 % sodium chloride as compared to a bolus injec-
tion minimises the cardiovascular side effects (first second-
ary safety endpoint) without compromising uterine tone
(primary efficacy endpoint) in women undergoing a
planned or unplanned caesarean delivery.
Methods/Design
Study design and setting
This is a prospective, single-centre, randomised, double-
dummy, investigator-initiated, non-inferiority trial con-
ducted at the University Hospital Basel, Switzerland. Study
recruitment commenced in December 2014 and is
expected to last for 16 months. The study was approved
by the regional Ethics Committee (Ethikkommission
Nordwestschweiz (EKNZ), EKNZ 2014–088, 13 March
2014). The study was registered in a national and an inter-
national trial registry (www.kofam.ch SNCTP000001197
and clinicaltrials.gov NCT02221531).
Randomisation and blinding
Randomisation for a 1:1 allocation of the study treatment is
provided through an online-randomiser to ensure alloca-
tion concealment. This online-randomiser was integrated
into the password-protected database. The randomisation
took place immediately before the CS after having con-
trolled the inclusion and exclusion criteria. The randomisa-
tion list was generated in Intercooled Stata Version 13.1
(StataCorp, College Station, TX, USA) using variable block
sizes between 2 and 8. The list is safely stored in a separ-
ate and sealed file, which will only be opened if unblinding
becomes necessary. This is considered to be unlikely since
the concomitant treatment in case of insufficient uterine
tone is independent of the mode of administration of
carbetocin.
Subjects are randomised on arrival in the operating
theatre to minimise the risk of dropouts after random-
isation. To achieve similar numbers, randomisation is
stratified for planned or unplanned CS (Fig. 1).
Two members of the study team (ES and SDK) ensure
correct administration of the study drug, transfer of the
haemodynamic parameters, and collect intraoperative data,
neither of whom is involved in the patients’ care. The study
nurse (ES) always prepares the study drug. Correspond-
ingly, patients, all care providers (obstetric and anaesthesia
team) as well as the statistician (SDK) will remain blinded
to group allocation until the data are analysed.
Selection and withdrawal of participants
Recruitment
Participants are identified at their pre-anaesthesia visit
and by screening the daily list of patients scheduled for a
CS (Fig. 1). The study staff or the anaesthetist in charge
informs the patients about all aspects pertaining to par-
ticipation in the trial and invites them to participate.
Informed consent
Eligibility is routinely assessed by the anaesthesia or obstet-
ric team in order to decide whether the patient is compe-
tent to provide consent to participate in the study. Written
informed consent will be obtained from all participants.
Participants are clearly informed that trial participation is
voluntary and that they are free to withdraw at any time
without effect on subsequent care. Recruitment of study
participants by all members of the research team is in line
with the guidance for Good Clinical Practice for obtaining
consent [13].
Inclusion criteria
Healthy women with a singleton pregnancy undergoing
a planned or unplanned CS after at least 37 completed
weeks of gestation under regional anaesthesia (spinal,
epidural or combined spinal-epidural anaesthesia) aged
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older than 18 years and with signed informed consent
are eligible.
Exclusion criteria
The following exclusion criteria are being applied: (1)
emergency CS, (2) unplanned CS due to fetal distress,
(3) maternal comorbidities such as severe cardiovascular
disorders including (pre-)eclampsia, kidney or liver dis-
orders, coagulopathies, as well as epilepsy, (4) uterine
malformation, (5) fetal malformation, (6) known hyper-
sensitivity to carbetocin or oxytocin, and (7) the inability
to read and understand the participant’s information.
Study procedure
Standard care
After arrival of the patient in the operating theatre, the
patient is positioned with a left uterine tilt to avoid
aorto-caval compression. A fluid co-load of 500 ml
hydroxyethyl starch HES 6 % is infused while the patient
is monitored with pulse oximeter, electrocardiogram and
non-invasive blood pressure cuff around the upper arm.
Spinal anaesthesia by single-shot technique using hyper-
baric bupivacaine 0.5 % 10 mg, fentanyl 10 mcg and
morphine 100 mcg is applied in right lateral position. If
an epidural catheter is already in place, 15–20 ml lido-
caine 2 % with carbon dioxide and adrenaline 1:200,000
are administered through the catheter after an intra-
thecal or intravasal displacement has been excluded.
After the application of the spinal anaesthesia, the pa-
tient is positioned in a left-tilted recumbent position.
The CS is performed according to the in-house standard
procedure applying the Misgav Ladach method for the
laparotomy [14]. Following uterine incision, delivery of
the baby and cord clamping, the placenta is delivered by
cord traction or manually, if necessary.
Study treatment in intervention and control group
After cord clamping, each patient will receive a 1-ml
bolus and a short-infusion of 100 ml 0.9 % sodium
chloride, one of which contains of carbetocin 100 mcg
and the other of placebo (double-dummy technique).
The study intervention only contains the mode of ad-
ministration of carbetocin. An independent study nurse
prepares the study medication (1-ml bolus and 100-ml
short-infusion with or without carbetocin 100 mcg). The
nurse is the only involved person with access to the ran-
domisation results. All syringes and short-infusions will
be labelled according to the Good Manufacturing
Fig. 1 Trial flow chart showing trial procedure of recruitment, stratified randomisation and follow-up visit
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Practice Guidelines with the study number (1–140) be-
ing the only differentiating feature between the study
drugs.
Concomitant treatments
In case of insufficient uterine tone, the patient will be
treated according to the current standard of care.
There are six options: (1) uterine massage, (2) sulpros-
tone 4–8 mcg/min, (3) 600 mcg misoprostol rectal, (4)
oxytocin infusion 20–40 U/2 h, (5) Bakri™ balloon, and
(6) surgical (including Tachosil®) or radiological (em-
bolisation) intervention. The choice of one or several
of these interventions is according to the severity of
uterine atony and at the discretion of the treating
obstetrician.
Laboratory analyses
Haemoglobin and haematocrit levels are measured pre-
operatively and 2 days postoperatively in order to esti-
mate the perioperative blood loss taking into account
the calculated pregnancy blood volume and the percent
blood volume lost [15, 16].
Follow-up visit
All participants have a follow-up visit 2 days postopera-
tively to rule out side effects of carbetocin and to ensure
that no further problems have arisen.
Data monitoring and stopping rules
The Ethics Committee agreed that monitoring would be
performed by the interdisciplinary study team. This team
will evaluate the progress of the trial, verify the accuracy
and completeness of the case report forms (CRFs), and
ensure that all protocol requirements and investigator’s
obligations are being fulfilled. The progress of the trial is
evaluated every second month. The overall distribution
of uterine tone will be assessed after 2 and 8 months in
a blinded way, i.e. without considering group allocation.
Extreme values are investigated further by reviewing the




The primary efficacy endpoint of this trial is the max-
imum uterine tone within the first 5 minutes after cord
clamping assessed by manual palpation, and rated on a
linear analogue scale (LAS) from 0 (completely atonic)
to 100 (fully contracted), by the obstetrician.
First secondary endpoint (or primary safety endpoint)
The haemodynamic parameters (lowest mean arterial
pressure and highest heart rate within the first 5 minutes
after administration of the study drug) are considered as
primary safety endpoints.
Further secondary endpoints
 Mean change over time of uterine tone measured 2,
3, 5 and 10 minutes after cord clamping
 Median dose of as well as number of patients
requiring vasoactive drugs during CS:
phenylephrine, ephedrine, atropine, nitroglycerine
during the time period before cord clamping,
between cord clamping until 1 minute after the end
of the short-infusion, and between the second meas-
urement and the end of surgery
 Mean estimated blood loss within the first 48 hours
calculated by multiplying the calculated maternal blood
volume by the percent of blood volume lost [15]
 Need for additional uterotonics (type and amount)
during or immediately after surgery
 Tolerability assessment intraoperatively and 2 days
postoperatively by monitoring the following side
effects of the study drug: ST segment analysis to
detect signs of myocardial ischaemia, angina pectoris,
facial flushing, headache, nausea and vomiting
 Administration of any blood product (i.e. packed red
cells, fresh frozen plasma) or coagulation factors
such as tranexamic acid or fibrinogen during or
immediately after surgery
 Median time and type of placenta removal, i.e. by
cord traction or manually
Measurement of uterine tone
The obstetrician provides an assessment of the uter-
ine tone by manual palpation using a LAS ranging
from 0 to 100. Manual palpation of the uterus is the
standard used to assess uterine tone in daily clinical
practice.
Haemodynamic measurements
Blood pressure is measured non-invasively using a cuff on
the upper arm. All haemodynamic data (including ST seg-
ment alterations) are recorded and stored in the anaesthe-
sia monitor (IntelliVue MX800, Philips AG Healthcare,
Zurich, Switzerland). The programme ixTrend from ixel-
lence (ixellence GmbH, Wildau, Germany) is used to




To be 80 % sure that the lower limit of a one-sided
97.5 % confidence interval (CI) will be above the non-
inferiority limit of −10 points on the LAS, 63 patients
per group are required assuming a standard deviation
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(SD) of 20. Offsetting a maximal dropout of 10 %, this
leads to a total sample size of 140 patients. The non-
inferiority margin has been defined to be −10 on the
LAS by the four most senior obstetricians at our institu-
tion. The SD had been derived from the results of a trial
by Butwick et al., who used the same scale to assess the
uterine tone [11].
Data management
All data from patients will be stored anonymously.
Each patient will be assigned a unique patient-identity
(ID) consisting of a three-digit number. The patient’s
ID, name and date of birth will be stored separately
in a different file in order to be able to examine
queries in case of implausible values (reversible anon-
ymisation). Only members of the study team have ac-
cess to the data.
An electronic database featuring web-based access
and using a secure (Secure Sockets Layer: SSL) connec-
tion is used for data entry. The database is password-
protected and all data are encrypted. A consistency
check is performed by logical data testing on the
browser and on a random sample of 5 % by an inde-
pendent study member.
Statistical analysis plan
The following baseline characteristics will be used to in-
vestigate comparability of both trial arms: age, body
mass index, parity, gravidity, gestational week, risk fac-
tors for PPH, number of previous CS, planned or un-
planned CS, reason for CS, experience level of the
obstetrician, batch number. Continuous variables will be
described by using the mean (SD) or median (interquar-
tile range) as appropriate, categorical variables by using
count (percentage).
In order to answer the primary research question, a CI
of the mean difference in LAS score of the maximal
uterine tone within the first 5 minutes after cord clamp-
ing will be calculated. If the lower limit of this CI does
not include the pre-specified non-inferiority limit of
−10, an inferiority of a short-infusion of more than 10
points on the LAS as compared to a bolus application is
unlikely. In order to improve efficiency, an additional
model will be built adjusting for the most relevant con-
founders, such as experience of the obstetrician, parity
or number of previous CS, number of risk factors for
PPH (multiple pregnancy, abnormal placentation, history
of PPH or uterine atony), duration of surgery, and dur-
ation of antenatal oxytocin infusion. In order to compare
the change of the uterine tone over time between both
study groups, a generalised estimation equation (GEE)
[17] will be built using an exchangeable correlation
matrix (with an interaction term between treatment
group and time). Moreover, the uterine tone over time
will be displayed graphically.
The haemodynamic secondary outcomes (lowest mean
arterial blood pressure and highest heart rate within the
first 5 minutes after the administration of the study
drug) will be analysed using a linear regression model
adjusting for the corresponding baseline value and the
amount of vasoactive drug administered during this
period. In a further analysis, the course over time of
mean arterial pressure and heart rate will be modelled
using a GEE model with an exchangeable correlation
matrix, using a knot at the average time of the low-
est mean arterial pressure adjusted for the dosage of
vasopressors administered, in order to compare the
trend over time in both groups. Moreover, the
change over time in blood pressure and heart rate
will be displayed graphically. The incidence of any
clinically relevant ST segment changes in both
groups will be compared using a chi-squared or a
Fisher’s exact test as appropriate. Further secondary
endpoints will only be analysed descriptively. The
comparison of the calculated blood loss will be ad-
justed in a linear regression model for whether or
not the mother is breastfeeding.
All analyses and graphs will be performed using Inter-
cooled Stata Version 13.1 for Mac (StataCorp, College Sta-
tion, TX, USA). We will follow the Consolidated
Standards of Reporting Trials (CONSORT) statement and
its extension for non-inferiority trials for the future report
[18, 19].
Definition of dataset analysed
A per-protocol and an intention-to-treat analysis will be
performed, and only if both approaches support non-
inferiority will the trial be considered as supporting our
non-inferiority hypothesis.
Reporting of adverse events
Participants are asked about any side effect including
(serious) adverse events immediately and 2 days postop-
eratively. All these events are recorded and monitored
until the patient has completely recovered or until no
causal relationship to the study drug administration has
been established. All serious adverse events will be re-
ported to the Ethics Committee and the sponsor within
the appropriate time frame.
The trial will be terminated early in the event of rele-
vant safety concerns that threaten the study partici-
pants in any way. Therefore, we will monitor the
incidence of PPH in a blinded manner and stop the
study early for safety concerns if the incidence rate
should rise above the average value of about 5 % PPH
in CS [20].
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Discussion
This randomised controlled investigator-initiated trial
prospectively evaluates how the uterine contractility and
haemodynamic parameters are affected by the mode of
administration of carbetocin in patients undergoing a
CS. Based on the findings of reduction in cardiovascular
side-effects with a short-infusion as compared to a bolus
injection found for oxytocin [12], our study hypothesis is
that a slower administration rate of carbetocin (using a
short-infusion) minimises cardiovascular side effects
without compromising uterine tone. In the following, we
discuss considerations regarding trial design and chosen
endpoints.
Choice of non-inferiority design
The aim of this trial is to reach greater haemodynamic
stability using the slower administration method (pri-
mary safety endpoint) while ensuring non-inferiority
with regard to the uterine tone (primary efficacy end-
point) and ultimately the risk of elevated blood loss.
Since superiority in haemodynamic endpoints can be
achieved with fewer patients, we decided to choose as
our primary endpoint non-inferiority in uterine tone.
Choice of primary endpoint
We consider the choice of the appropriate measurement of
our primary endpoint as a main challenge in this trial. The
choice of our primary outcome is based on a randomised
controlled trial performed by Butwick et al. [11] who also
used a LAS ranging from 0 to 10 to assess uterine tone in a
similar setting. We expanded the scale from 0 to 100 to
avoid the fact that some outcome assessors used decimal
places (e.g. 7.5) while others did not. Moreover, manual pal-
pation of the uterus represents the standard method to
assess uterine tone in daily clinical practice. To reduce bias,
especially when using a subjective primary outcome meas-
urement, we have established and will maintain blinding by
using a double-dummy technique for study drug adminis-
tration in patients and all care providers until the statistical
analysis has been performed. We have chosen to abstain
from a binary assessment of the uterine tone as it would be
too parallel to our secondary outcome variable ‘any add-
itional uterotonics – yes/no’. The objective efficacy out-
come of interest would have been intraoperative blood loss.
Blood loss during PPH is often estimated visually, but visual
assessment has been shown to be imprecise, usually under-
estimating blood loss particularly concerning larger vol-
umes [21–24]. We have, therefore, decided to choose the
uterine tone as our primary outcome variable. We consider
blood loss as a secondary endpoint, calculated by taking
into account the pre- and postoperative haematocrit and
the estimated blood volume of the parturient [15].
Haemodynamic measurement method
We chose haemodynamic stability, defined as lowest mean
arterial pressure and highest heart rate within the first 5 mi-
nutes after the administration of the carbetocin. After
evaluating the options for continuous invasive and non-
invasive blood pressure measurements, we have decided to
measure blood pressure non-invasively using a cuff on the
upper arm. We have considered the accuracy and the preci-
sion of the continuous non-invasive methods insufficient to
justify their use in the context of this trial. Although the
risk for complications of an intra-arterial catheter is low
[25], the potentially severe side effects do not justify inva-
sive blood pressure monitoring.
This sample size allows showing a superiority of the
short-infusion over the bolus administration in mean
Fig. 2 Target and actual recruitment rate to achieve the given sample size within the planned recruitment period
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arterial blood pressure by at least 5 mmHg with 80 %
power and a type-1 error of 5 % assuming a SD of 10.
Thus, even a clinically irrelevant difference in efficacy
could be found with our data. However, we need to ac-
knowledge that we are not able to show a minor differ-
ence in the incidence of serious drops in blood pressure
with our sample size.
Choice of study population
This trial will include patients undergoing a planned and
an unplanned CS. Patients undergoing a unplanned CS
often have already received oxytocin to induce or en-
hance labour, thus, showing a different response to the
intraoperative dosage of carbetocin. Therefore, we are
using a stratified randomisation for planned and un-
planned CS. Excluding these patients would limit the
generalisability of our study results.
Recruitment
Poor recruitment is the most frequently reported cause
for discontinuation of a clinical trial [26]. However, due
to good interdisciplinary cooperation, adequate personal
and financial resources and a high acceptance for clinical
research, we are able to exceed the target recruitment
rate (Fig. 2). Additionally, an amendment was handed in
shortly after the beginning of the recruitment to incorp-
orate patients with a breech position fetus. Within the
same amendment, we have also translated the study in-
formation and the consent into English to be able to ad-
dress more patients.
Implications for future clinical practice
Haemodynamic stability and adequate uterine contractil-
ity are important outcomes in CS. The results of this
trial may be used to optimise these factors and thereby
increase safety in parturients due to reduced cardiovas-
cular side effects.
Trial status
The trial is currently enrolling patients. Upon submis-
sion of this manuscript, 60 % of the patients have been
enrolled. The average enrolment rate is three (range one
to seven) patients every week.
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